natgillin/translations-raw huggingface dataset:
and R3 are independently hydrogen, halogen, or C1-C6 alkyl wherein said C1-C6 alkyl is substituted with 0-6 halogen; 
i R3 su neovisno halogen ili skupina C1-C6 alkil, pri čemu je navedena skupina C1-C6 alkil supstituirana s 0-6 halogena;
According to the present invention at least one fragment is derived from amino acid residues 150 to 170 and at least one fragment is derived from amino acid residues 205 to 225 of PCSK9 (SEQ ID No. 9). 
SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 205 do 225 od PCSKO u skladu sa SEQ ID NO:9.
rearranging synonymous codons from the protein encoding sequence of the parent virus to obtain a modified protein encoding sequence, wherein said rearrangement provides a reduced codon pair bias relative to a mammalian host over the modified protein encoding sequence, in comparison to the encoding region of the parent virus, without changing codon usage of the parent virus, wherein the codon pair bias is calculated by the following formula: EPMATHMARKEREP wherein, the codon pair bias (CPB) of a protein encoding sequence is the arithmetic mean of the codon pair scores (CPS) of the individual codon pairs (i) contained within said protein encoding sequence of k codons in length; and 
kodira istu sekvencu aminokiseline kao kodirajuća regija matičnog virusa, i ii) ima smanjenu pristranost para kodona u usporedbi s kodirajućom regijom matičnog virusa; pri čemu se pristranost para kodona (CPB) izračunava pomoću slijedeće formule za sekvencu duljine k aminokiselina, pri čemu CPS predstavlja rezultat para kodona; pri čemu preraspodijeljeni kodoni u sekvenci koja kodira modificirani protein osiguravaju pristranost para kodona koja je smanjena za barem 0,05 u usporedbi s pristranosti para kodona za sekvencu koja kodira matični protein; pri čemu se koraci (a) i (b) primjenjuju na računalu, i
hydrogenation of a compound of formula III to provide a compound of formula II: 
(v) -hidrogeniranje spoja formule III kako bi se dobilo spoj formule II:
The strip is closed in a tube and welded on or around the steel core. 
Mreža za akvakulturu (10) prema zahtjevu 1, gdje je traka zavarena na i oko čelične jezgre (14).
Typical therapeutic agents include, among others, anti-neoplastic agents such as doxorubicin, cisplatin, taxotere, 5-fluoruracil, methotrexat, gemzitabin and cyclophosphamide. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 8, naznačeno time, što kemoterapeutsko sredstvo je odabrano iz skupine koja se sastoji od doksorubicina, cisplatina, taksotere, 5fluoruracila, metotreksata, gemcitabine i ciklofosfamida.
The anamorelin monohydrochloride of claim 1 in combination with one or more pharmaceutically acceptable excipients in the form a tablet or capsule or pellets or granules or powders. 
4. - Farmaceutski sastav koji sadrži: a) terapeutski efikasnu količinu anamorelin monohidroklorida prema patentnim zahtjevima 1, 2 ili 3; 1 b) jedan ili više farmaceutski prihvatljivih ekscipijenata.
for use as an anti-inflammatory; for use in treatment of one or more of tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, candidiasis (moniliasis), Candida albicans, tinea (pityriasis) vesicolor, or Malassezia furfur; 
i Microsporuma canis, kandidijaze (monilijaze), Candide albicans, tineje (pitirijaze) versicolor, ili Malassezie furfur; za uporabu u liječenju akutne mijeloične leukemije ili akutne limfatične leukemije; za uporabu u liječenju kronične mijeloične leukemije, limfoma ili multiplog mijeloma.
Examples of sorbitan fatty acid esters include sorbitan monolaurate, sorbitan monooleate, and sorbitan monopalmitate (Span 40), or a combination thereof. 
- pri čemu sorbitan ester masne kiseline sadrži sorbitan monolaurat, sorbitan monooleat ili sorbitan monopalmitat ili njihovu kombinaciju, ili
The process according to claim 14, wherein one aliphatic carboxylic acid is stearic acid and the other one is selected from the group consist565236-A1 
Postupak prema zahtjevu 7, gdje je jedna alifatska karboksilna kiselina stearinska kiselina i druga se izabire iz grupe koja obuhvaća oktansku kiselinu, miristinsku kiselinu, palmitinsku kiselinu, arahidonsku kiselinu, behensku kiselinu i lignocerinsku kiselinu.
the single nucleotide polymorphism marker having a T at the position corresponding to position 82 in SEQ ID NO: 6, and 
marker polimorfizma jednostrukog nukleotida koji ima T na položaju koji odgovara položaju 82 u SEQ ID NO: 6, i
The pharmaceutical composition for use according to claim 1, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-2,1-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 50 ng/mL to 250 ng/mL. 
Farmaceutski sastav za uporabu prema patentnom zahtjevu 1, naznačen time, da sastav daje stacionarno stanje razine u plazmi 3a-hidroksi-3f-metoksimetil-21-(1'-imidazolil)-5a-pregnan-20-ona u području od 50 ng/ml do 250 ng/ml.
Crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione for use of claim 7 or 8, wherein method involves administering the crystalline 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione oral, parenteral or sublingual route of administration. 
Upotreba u skladu s bilo kojim od patentnih zahtjeva 38 do 43, naznačena time što se kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion pripravlja za oralnu, parenteralnu, nazalnu, topikalnu ili sublingvalnu primijenu.
two -W'-X'-Y'-Z' are attached to the same atom and optionally form a 3-20 membered cycloalkyl or heterocycloalkyl group optionally substituted by 1, 2 or 3 -W"-X"-Y"-Z"; or 
Spoj iz zahtjeva 1 ili njegova farmaceutski prihvatljiva sol, gdje su dva -W’-X’-Y’-Z’ vezana za isti atom i opcionalno formiraju 3-20-očlani cikloalkil ili heterocikloalkil grupu opcionalno supstituiranu sa 1, 2 ili 3 -W’’-X’’-Y’’-Z’’.
The compound according to claim 1 which is vortioxetine (DL)-pyroglutamate a-form in crystalline form with XRPD reflections at 14.27, 15.75, 17.06 and 18.59 (°2θ) (±0.1 °2θ). 
Spoj prema patentnom zahtjevu 1, naznačen time što je a-oblik vortioksetin (DL)-piroglutamata u kristalnom obliku s XRPD refleksijama kod 14,27, 15,75, 17,06 i 18,59 (220) (+0,1 220).
A second foil lined tube, 50 mm in length, was inserted over the cellulose acetate tube until it abutted against the 20 mm foil lined tube. 
Druga cijev obložena folijom, dužine 50 mm, umetne se preko cijevi od acetat celuloze dok ne dodirne 20 mm dugu cijev koja je obložena sa folijom.
The pharmaceutical composition of clause 45, further comprising a solvent, diluent, excipient, carrier, or solubilizing agent. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što dodatno sadrži drugo otapalo, razrjeđivač, pomoćnu tvar, podlogu ili solubilizacijsko sredstvo.
is independently selected from optionally substituted C1-C8 alkyl, optionally substituted C6-C12 acryl, optionally substituted hetero C5-C10 aryl, optionally substituted C3-C10 cycloalkyl, and optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
je nezavisno odabran od proizvoljno supstituiranog C1-C8 alkila, proizvoljno supstituiranog C6-C12 arila, proizvoljno supstituiranog hetero C5-C10 arila, proizvoljno supstituiranog C3-C10 cikloalkila i proizvoljno supstituiranog hetero C3-C10 cikloalkila, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
Compounds according to Claim 1, selected from the group 
Spojevi prema zahtjevu 1, naznačeni time da se biraju iz skupine koju čine
WO 200307467 (Aebi et al.) teaches a prokaryotic organism into which is introduced a nucleic acid encoding for (i) specific glycosyltransferases for the assembly of an oligosaccharide on a lipid carrier, (ii) a recombinant target protein comprising a consensus sequence “N-X-S/T”, wherein X can be any amino acid except proline, and (iii) an oligosaccharyl transferase, such as, for example, an oligosaccharyl transferase of C. jejuni that covalently links said oligosaccharide to the consensus sequence of the target protein. Said prokaryotic Organism produces N-glycans with a specific structure which is defined by the type of the specific glycosyltransferases. 
Rekombinantni prokariotski organizam, naznačen time što je bakterija £. coli koja sadrži nukleinske kiseline koje kodiraju: i) = epimerazu koja sintetizira N-acetilgalaktozamin na undekaprenil-pirofosfatu, gdje je navedena nukleinska kiselina koja kodira navedenu epimerazu najmanje 95% istovjetna sa SEQ ID NO: 1; ii) - glikozil-transferaze koje slažu oligo- ili polisaharid na lipidnom nosaču; iii) oligosaharil-transferazu iz bakterije Campilobacter jejuni; i iv) protein koji sadrži jedan ili više rekombinantno uvedenih konsenzusnih sljedova, D/E-X-N-Z-S/T, gdje su X i Z neovisno bilo koja prirodna aminokiselina osim prolina, gdje oligosaharid složen navedenim glikozil-transferazama oligosaharil-transferaza može prenijeti s lipidnog nosača na ciljani protein koji ima jedan ili više optimiziranih konsenzusnih sljedova.
Following “break-in”, which was done at a holding potential of −80 mV (set by the amplifier), and appropriate adjustment of series resistance and capacitance controls, electrophysiology software (Clampex, Axon Instruments) was used to set a holding potential (−80 mV) and to deliver a voltage protocol. 
Nakon "proboja", koji je napravljen pri zadržanom potencijalu od - $0mV (postavljen od strane pojačala), i prikladnog podešenja kontrola serijskog otpora i kapacitancije, za podešavanje zadržanog potencijala i primjenu voltažnog protokola korišten je elektrofiziološki softver (Clampex, Axon Instruments).
The aqueous pharmaceutical suspension according to claim 7, wherein the edetate disodium is, by weight/volume (g/100 mL), about 0.12% to about 0.18%. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što dinatrijev edetat iznosi, težinski/volumno (£/190 ml), otprilike 0,12 % do otprilike 0,18 %.
lixisenatide or/and a pharmaceutically acceptable salt thereof, and insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) is present in a concentration of 100 U/ml, and compound (a) is present in a concentration of 50 µg/ml, for use in the treatment of diabetes mellitus type 2, wherein the pharmaceutical composition is administrated as add-on to the treatment with metformin or/and a pharmaceutically acceptable salt thereof. 
(a) liksisenatid ili/i njegovu farmaceutski prihvatljivu sol, i (b) inzulin glargin ili njegovu farmaceutski prihvatljivu sol, pri čemu je spoj (b) prisutan u koncentraciji od 100 U/ml, i spoj (a) je prisutan u koncentraciji od 50 ug/ml, naznačen time što je za upotrebu u liječenju dijabetes melitusa tipa 2, pri čemu se farmaceutski pripravak primjenjuje kao dodatak liječenju metforminom ili njegovom farmaceutski prihvatljivom soli.
amino acids 177-274 of OspA from B. garinii, strain PBr (SEQ ID NO: 8) with a substitution of the threonine residue at amino acid 233 with a proline residue, wherein the second OspA fragment is mutant and cystine-stabilized in that it differs from the corresponding wild-type sequence at least by the substitution of the wild-type amino acid at position 182 +/- 3 of SEQ ID NO: 8 by a cysteine and by the substitution of the wild-type amino acid at position 269 +/- 3 of SEQ ID NO: 8 by a cysteine and wherein a disulfide bond between the cysteine at position 182 +/-3 and the cysteine at position 269 +/-3 of said second OspA fragment is present; and 
aminokiseline 177-274 od OspA iz B. garinii soja, PBr (SEQ ID NO: 8), sa supstitucijom treonina s ostatkom aminokiselini 233 sa ostatkom prolina, pri čemu je drugi OspA fragment mutant i cistin stabiliziran time što se razlikuje od odgovarajuće sekvenca divljeg tipa supstituiran barem aminokiselinom divljeg tipa na položaju 182 +/- 3 od SEQ ID NO: 8 pomoću cisteina i supstitucijom aminokiseline divljeg tipa na položaju 269 +/- 3 od SEQ ID NO: 8 pomoću cistein 1 gdje je disulfidna veza između cisteina na položaju 182 +/- 3 1 cisteina na položaju 269 +/- 3 navedenog drugog OspA fragmenta; i pri čemu je numeriranje aminokiselina 1 cisteinskih supstitucija u skladu s numeracijom odgovarajućih aminokiselina pune dužine OspA od B. burgdorferi s.s. soja B31 (SEQ ID NO: 5).
In embodiments of the description, the active compound or a salt can be administered in combination with another antiviral agent such as ribavirin, another nucleoside HCV polymerase inhibitor, a HCV non-nucleoside polymerase inhibitor, a HCV protease inhibitor, a HCV helicase inhibitor or a HCV fusion inhibitor. 
Primjena prema patentnom zahtjevu 15, naznačena time što je antivirusni spoj izabran iz grupe koju čine inhibitor HCY proteaze, drugi nukleozidni inhibitor HCV polimeraze, ne-nukleozidni inhibitor HCV polimeraze, inhhibitor HCY helikaze, inhibitor HCV primaze i inhibitor HCY fuzije.
Step b) of converting maltose to glucose may be performed in any of the ways described above in the section “Converting sugar to glucose”, and in particular step b) may comprise contacting the starting liquid with an enzyme capable of catalysing hydrolysis of maltose to glucose as described in the section “Converting sugar to glucose”, 
Postupak prema bilo kojem od zahtjeva 3 do 5, naznačen time što korak b) sadrži pretvaranje navedene maltoze u glukozu dovođenjem u kontakt navedene početne tekućine s mikroorganizmom koji katabolizira maltozu koji je sposoban za pretvaranje maltoze u glukozu, pri čemu je navedeni mikroorganizam koji katabolizira maltozu na primjer Lactobacillus sanfransiscensis.
A process for preparing (S)-3-aminomethyl-5-methylhexanoic acid (pregabalin) comprising the steps of: 
Postupak dobivanja (S)-3-aminometil-5-metilheksanske kiseline (pregabalina), koji se sastoji u koracima:
Method according to anyone of claims 1 to 4, wherein the concentrator (C) transmits a start time and an end time to the remote meter (RM) requesting transmission of consumption related data from said start time to said end time. 
Metoda prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu sabirnik (C) prenosi vrijeme početka 1 vrijeme završetka u daljinski brojač (RM) zahtijevajući prijenos navedenih periodički izmjerenih i pohranjenih podataka vezanih uz potrošnju od navedenog vremena početka do završetka.
the friction element has a pattern corresponding to the friction pattern on the stem. 
- tarni element (5) ima uzorak koji odgovara naboranom uzorku (7) na dršci (2).
A newer strategy has been the development of dual re-uptake inhibitors, e.g., the combined effect of serotonin reuptake inhibition and norepinephrine (norepinephrine is also named noradrenaline, NA) reuptake inhibition on depression is explored in clinical studies of compounds such as Duloxetine (Wong, “Duloxetine (LY-248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate”, Expert Opinion on Investigational Drugs, 1998, 7, 10, 1691-1699) and Venlafaxine (Khan-A et al, 30 “Venlafaxine in depressed outpatients”, Psychopharmacology Bulletin, 1991, 27, 141-144). 
Novija strategija je u razvoju dualne re-apsorpcije inhibitora, npr. kombinirani učinak inhibicije re-apsorpcije serotonina i norepincfrina (norepincfrin je također poznat I kao noradrenalin, NA) na depresiju istražuje sc u kliničkim studijama spojeva kao stoje to Duloxetin (Wong,,,Duloxetine (LY-248686) inhibitor serotonina i apsorpcije noradrenalina i kandidat za antidepresivni lijek",,,Expert Opinion on Investigational Drugs, 1998,7,70,1691-1699) 1 Venlafaxine (Khan-A et al. 30,,Venlafaxin kod depresivnih ambulantnih pacijenata", Psychopharmacology Bulletin, 1991,27,141-144).
A compound of Claim 4, wherein R1 is substituted or unsubstituted tetrahydrofuran or substituted or unsubstituted tetrahydrofuranyloxy. 
Spoj prema Zahtjevu 4, naznačen time, da R1 je supstituirani ili nesupstituirani tetrahidrofuran ili supstituirani ili nesupstituirani tetrahidrofuraniloksi.
A replication competent virus according to any one of claims 1 to 18, or a pharmaceutical composition according to claim 19, for use in treatment. 
Replikacijski kompetentni adenovirus u skladu s patentnim zahtjevom 1 do 18 ili pripravak u skladu s patentnim zahtjevom 19, naznačeni time što su namijenjeni upotrebi u liječenju.
A plant according to claim 1, wherein the heat exchangers included in the closed coolant loop are semi welded plate heat exchangers. A plant according to claim 1, wherein the at least one booting pump is multistage centrifugal pumps. 
Postrojenje prema bilo kojem od prethodnih zahtjeva, naznačeno time što su izmjenjivači topline (D, G1, G2) koji su uključeni u zatvoreni krug rashladnog sredstva polu zavareni pločasti izmjenjivači topline.
means for determining and adjusting the flow-rates of the gases that enter the mixing system (1), said gases being one or more of nitrogen, carbon dioxide, nitrous oxide, oxygen and hydrocarbon, as a function of the type of thermal treatment and of the concentration of carbon monoxide, carbon dioxide, methane and nitrous oxide and optionally of the dew point and/or of the concentration of oxygen, and of the temperature in the treatment furnace, as detected. 
sredstva za određivanje i prilagođavanje protoka plinova koji ulaze u sustav miješanja (1), pri čemu su navedeni plinovi jedan ili više između dušika, ugljičnog dioksida, dušikovog oksida, kisika i ugljikovodika, kao funkcija vrste toplinske obrade i koncentracije ugljikovog monoksida, ugljičnog dioksida, metana i dušikovog oksida 1 po izboru točke rosišta i / ili koncentracije kisika i temperature u peći za obradu, kako je izmjereno i -
The water soluble film forming agent may be selected from any water soluble film forming agent known in the art. 
Vodotopivi agens koji tvori film može biti bilo koji vodotopivi agens koji tvori film poznat u struci.
Compounds of the Formula III are commercially available or may be prepared using standard techniques, for example as illustrated in U.S. Pat. No. 5,252,586 and WO 94/27965. 
Spojevi prikazani Formulom III su komercijalno dostupni ili ih se može pripraviti koristeći standardne tehnike, ilustrirane u, na primjer, US 5,252,586 i WO 94/27965.
the amino, imino, aminosulfonyl, aminocarbonyl, carbocyclyl, and heterocyclyl optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, alkylsulfonylamino, hydroxy, and alkyloxy, 
amino, imino, aminosulfonil, aminokarbonil, karbociklil i heterociklil su opcijski supstituirani s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju alkil, alkenil, alkinil, alkilsulfonil, alkenilsulfonil, alkinilsulfonil, alkilsulfonilamino, hidroksi i alkiloksi, pri čemu:
(1.02 mm) hole was drilled down the center of the element. 
Otvor od 1.02 mm izbušen je niz centar elementa.
The method of any one of embodiments 90 to 99, wherein the lipid component and the protein component represent the majority of lipids and proteins and peptides, respectively, in said starting suspension of step (a). 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time što nadalje sadrži, prije koraka (a), korak oblikovanja navedene početne suspenzije postupkom koji obuhvaća miješanje lipidne komponente i proteinske komponente.
A solid pharmaceutical composition in dosage unit form, comprising, per dose, from 1 mg to 1000 mg of a hemisulfate salt of Compound (I): and a pharmaceutically acceptable carrier or diluent. 
HR P20191655 T1 PATENTNI ZAHTJEVI no Čvrsta farmaceutska kompozicija u doznom jediničnom obliku, koja sadrži, po dozi, od 1 mg do 1000 mg hemisulfat soli spoja (I): i farmaceutski prihvatljiv nosač ili razblaživač.
The pharmaceutical composition of any one of claims 1 to 9, wherein said anti-human-IL13 antibody is a multispecific antibody which is a bispecific antibody. 
Antagonističko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 13, naznačeno time što je multispecifično protutijelo koje je bispecifično protutijelo.
The solution is concentrated in vacuo to remove ethyl acetate and provide a solid (93%). 
Otopinu se koncentrira u vakuumu kako bi se uklonilo etil-acetat i dobilo krutinu (93 %).
placing a substance that includes sodium bicarbonate in the chamber; 
stavljanje natrijevog bikarbonata u komoru (21; 204; 304);
or a pharmaceutically acceptable salt thereof. The compound of claim 1 having formula (VIII) 
AJ o (VID ili njegova farmaceutski prihvatljiva sol; ili formulu (VIII)
complementarity determining region (CDR) 3 set forth in SEQ ID NO: 194 of the VH of antibody ID 8. 
region koji određuje komplementarnost (CDR) 3 naveden u SEQ ID NO: 158 VH antitijela ID 6.
The day after the cleaning, the column containing recycled Fibra-Cel® disks was sterilized and kept sterile until start of the new run. 
Dan nakon čišćenja, kolona koja je sadržavala diskove Fibra-Cel" bila je sterilizirana te održavana sterilnom sve do početka nove runde uzgoja.
21 Properties on application of the paint formulation 
Datum objave europske prijave patenta:
the method comprising the step of reacting a compound of formula (III) with a 2-ethylhexanoate salt: 
postupak sadrži korak reakcije spoja formule (III) sa 2-etilheksanoatnom soli:
The soft chewable veterinary composition of any one of claims 1-26, wherein the compound of Formula (I) is present at a concentration of about 10% to about 20% by weight. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 1, naznačen time, da je spoj formule (I) prisutan u koncentraciji od oko 10% do oko 20% po masi.
System and method for assessment of smoking articles 
SUSTAV I POSTUPAK ZA PROCJENU ARTIKALA ZA PUÅ ENJE
A diagnostic composition comprising a Compound I 
PATENTNI ZAHTJEVI Dijagnostički sastav obuhvaća Tvar 1
providing an aqueous mixture at a first pressure (P1), the aqueous mixture comprising water and von Willebrand factor (vWF) at a first concentration (C1) relative to the water; 
pružanje vodene mješavine pri prvom tlaku (P1), pri čemu vodena mješavina sadrži vodu i von Willebrandov faktor (vWF) pri prvoj koncentraciji (C1) u odnosu na vodu;
determining (1920) a location of the last significant transformation coefficient by decoding the information about the horizontal axis direction location and the vertical axis direction location; decoding the last significant transformation coefficient based on the location of the last significant transformation coefficient; decoding a significant coefficient flag, included in the received bitstream, representing a location of a second significant transformation coefficient; and 
dekodiranje zadnjeg značajnog koeficijenta transformacije na temelju lokacije zadnjeg značajnog koeficijenta transformacije; dekodiranje indikatora značajnog koeficijenta, uključenog u primljeni tok bitova, predstavljajući lokaciju drugog značajnog koeficijenta transformacije; i dekodiranje drugog značajnog koeficijenta transformacije korištenjem indikatora značajnog koeficijenta;
Method for evaluating muscle relaxant efficacy 
Metoda za ocjenjivanje učinkovitosti relaksanta mišića
The method of claim 11, wherein the at least one of the at least two pump segments (103) comprises a first pump segment (103a) and wherein the at least one other pump segment comprises a second pump segment (103b) and wherein respective peaks of the pulses (601a, 601b) provided through the first pump segment and the second pump segment are approximately 180 degrees out of phase. 
Postupak prema zahtjevu 11, naznačen time, da prema kojem barem jedan od najmanje dva segmenta (103) sisaljke sadrži prvi segment (103) sisaljke i gdje barem jedan od sljedećeg segmenta sisaljke sadrži drugi segment (103b) sisaljke 1 pri čemu su odgovarajuće vršne vrijednosti pulseva (601a, 601b) dobivenih kroz prvi segment sisaljke i drugi segment sisaljke otprilike 180 stupnjeva izvan faze.
mixing a coarse excipient and a microfine excipient and sieving the resulting mixture; 
(1) miješanje grubog ekscipijensa i mikrofinog ekscipijensa i prosijavanje nastale smjese;
The eluate is counted in a scintillation counter. 
Eluat je izmjeren na scintilacijskom brojaču.